8025 Background: Daratumumab (D) is a human CD38-targeting mAb that significantly
prolongs progression-free survival (PFS) when added to standard-of-care regimens in …

Daratumumab is a CD38‐targeting monoclonal antibody approved for intravenous (IV)
infusion for multiple myeloma (MM). We describe the Phase II PLEIADES study of a …

Background In the primary analysis of the phase 3 MAIA trial (median follow-up 28· 0
months), a significant improvement in progression-free survival was observed with …

Background Standard-of-care treatment for patients with newly diagnosed multiple myeloma
includes combination therapies for patients who are not eligible for autologous stem-cell …

We evaluated the efficacy and safety of 24 cycles of Dara in combination with carfilzomib (K),
lenalidomide (R), and dexamethasone (d) without autologous stem cell transplant (ASCT) in …

Background Lenalidomide plus dexamethasone is a standard treatment for patients with
newly diagnosed multiple myeloma who are ineligible for autologous stem-cell …

Daratumumab in combination with lenalidomide‐dexamethasone (D‐Rd) recently received
FDA approval for the treatment of transplant‐ineligible patients with newly diagnosed …

Introduction: Daratumumab (DARA) is a human IgGκ monoclonal antibody targeting CD38
with a direct on-tumor and immunomodulatory mechanism of action. The addition of DARA …

Introduction: Daratumumab is a first-in-class monoclonal antibody targeting the plasma cell
antigen, CD38, that demonstrated significant activity in combination with bortezomib and …

In the phase 3 POLLUX study, daratumumab plus lenalidomide and dexamethasone (DRd)
significantly reduced the risk of progression/death and induced deeper responses vs …